PURPOSE: Hypermethylation of tumor suppressor gene promoters has been found in head and neck squamous carcinoma (HNSCC) and other solid tumors. We evaluated these alterations in pretreatment salivary rinses from HNSCC patients by using real-time quantitative methylation-specific PCR (Q-MSP). EXPERIMENTAL DESIGN: Pretreatment saliva DNA samples from HNSCC patients were evaluated for patterns of hypermethylation by using Q-MSP. Target tumor suppressor gene promoter regions were selected based on a previous study describing a screening panel for HNSCC in a high-risk population subjects. The selected genes were: DAPK, DCC, MINT-31, TIMP-3, p16, MGMT, CCNA1. RESULTS: We analyzed the panel in a cohort of 61 HNSCC patients. Thirty-three of the analyzed patients (54.1%) showed methylation of at least one of the selected genes in the saliva DNA. Pretreatment methylated saliva DNA was not significantly associated with tumor site (P = 0.209) nor clinical stage (P = 0.299). However, local disease control and overall survival were significantly lower in patients presenting hypermethylation in saliva rinses (P = 0.010 and P = 0.015, respectively). Multivariate analysis confirmed that this hypermethylation pattern remained as an independent prognostic factor for local recurrence (HR = 12.2; 95% CI = 1.8-80.6; P = 0.010) and overall survival (HR = 2.8; 95% CI = 1.2-6.5; P = 0.016). CONCLUSIONS: We were able to confirm an elevated rate of promoter hypermethylation in HNSCC saliva of patients by using a panel of gene promoters previously described as methylated specifically in HNSCC. Detection of hypermethylation in pretreatment saliva DNA seems to be predictive of local recurrence and overall survival. This finding has potential to influence treatment and surveillance of HNSCC patients.
PURPOSE: Hypermethylation of tumor suppressor gene promoters has been found in head and neck squamous carcinoma (HNSCC) and other solid tumors. We evaluated these alterations in pretreatment salivary rinses from HNSCC patients by using real-time quantitative methylation-specific PCR (Q-MSP). EXPERIMENTAL DESIGN: Pretreatment saliva DNA samples from HNSCC patients were evaluated for patterns of hypermethylation by using Q-MSP. Target tumor suppressor gene promoter regions were selected based on a previous study describing a screening panel for HNSCC in a high-risk population subjects. The selected genes were: DAPK, DCC, MINT-31, TIMP-3, p16, MGMT, CCNA1. RESULTS: We analyzed the panel in a cohort of 61 HNSCC patients. Thirty-three of the analyzed patients (54.1%) showed methylation of at least one of the selected genes in the saliva DNA. Pretreatment methylated saliva DNA was not significantly associated with tumor site (P = 0.209) nor clinical stage (P = 0.299). However, local disease control and overall survival were significantly lower in patients presenting hypermethylation in saliva rinses (P = 0.010 and P = 0.015, respectively). Multivariate analysis confirmed that this hypermethylation pattern remained as an independent prognostic factor for local recurrence (HR = 12.2; 95% CI = 1.8-80.6; P = 0.010) and overall survival (HR = 2.8; 95% CI = 1.2-6.5; P = 0.016). CONCLUSIONS: We were able to confirm an elevated rate of promoter hypermethylation in HNSCC saliva of patients by using a panel of gene promoters previously described as methylated specifically in HNSCC. Detection of hypermethylation in pretreatment saliva DNA seems to be predictive of local recurrence and overall survival. This finding has potential to influence treatment and surveillance of HNSCC patients.
Authors: C Jerónimo; H Usadel; R Henrique; J Oliveira; C Lopes; W G Nelson; D Sidransky Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: Susan V Harden; Yutaka Tokumaru; William H Westra; Steven Goodman; Steven A Ahrendt; Stephen C Yang; David Sidransky Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird Journal: Nucleic Acids Res Date: 2000-04-15 Impact factor: 16.971
Authors: A K El-Naggar; L Mao; G Staerkel; M M Coombes; S L Tucker; M A Luna; G L Clayman; S Lippman; H Goepfert Journal: J Mol Diagn Date: 2001-11 Impact factor: 5.568
Authors: S L Rosas; W Koch; M G da Costa Carvalho; L Wu; J Califano; W Westra; J Jen; D Sidransky Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: W A Palmisano; K K Divine; G Saccomanno; F D Gilliland; S B Baylin; J G Herman; S A Belinsky Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701
Authors: Janice M Yoshizawa; Christopher A Schafer; Jason J Schafer; James J Farrell; Bruce J Paster; David T W Wong Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132
Authors: Wenyue Sun; Daria A Gaykalova; Michael F Ochs; Elizabeth Mambo; Demetri Arnaoutakis; Yan Liu; Myriam Loyo; Nishant Agrawal; Jason Howard; Ryan Li; Sun Ahn; Elana Fertig; David Sidransky; Jeffery Houghton; Kalyan Buddavarapu; Tiffany Sanford; Ashish Choudhary; Will Darden; Alex Adai; Gary Latham; Justin Bishop; Rajni Sharma; William H Westra; Patrick Hennessey; Christine H Chung; Joseph A Califano Journal: Cancer Res Date: 2013-12-18 Impact factor: 12.701
Authors: Daria A Gaykalova; Judith B Manola; Hiroyuki Ozawa; Veronika Zizkova; Kathryn Morton; Justin A Bishop; Rajni Sharma; Chi Zhang; Christina Michailidi; Michael Considine; Marietta Tan; Elana J Fertig; Patrick T Hennessey; Julie Ahn; Wayne M Koch; William H Westra; Zubair Khan; Christine H Chung; Michael F Ochs; Joseph A Califano Journal: Int J Cancer Date: 2015-06-23 Impact factor: 7.396
Authors: Wenyue Sun; David Zaboli; Hao Wang; Yan Liu; Demetri Arnaoutakis; Tanbir Khan; Zubair Khan; Wayne M Koch; Joseph A Califano Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Jong-Lyel Roh; Xin Victoria Wang; Judith Manola; David Sidransky; Arlene A Forastiere; Wayne M Koch Journal: Clin Cancer Res Date: 2013-02-26 Impact factor: 12.531
Authors: Scott M Langevin; Rondi A Butler; Melissa Eliot; Michael Pawlita; Jennifer Z J Maccani; Michael D McClean; Karl T Kelsey Journal: Oral Oncol Date: 2014-09-18 Impact factor: 5.337